Statins × cardiovascular events

SynthesisThe Cochrane database of systematic reviews2014

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.

Suetonia C Palmer et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 45,285 people · 2014

Randomised comparison

Reduced cardiovascular events

−28%−34% to −21%

Bigger than 6 in 10 for cardiovascular events

As reported

RR 0.72, 95% CI 0.66–0.79

Randomised comparison

Reduced cardiovascular events

−21%−31% to −9%

Bigger than 5 in 10 for cardiovascular events

As reported

RR 0.79, 95% CI 0.69–0.91

Randomised comparison

Reduced cardiovascular events

−23%−31% to −13%

Bigger than 5 in 10 for cardiovascular events

As reported

RR 0.77, 95% CI 0.69–0.87

Randomised comparison

Reduced cardiovascular events

−45%−58% to −28%

Bigger than 9 in 10 for cardiovascular events

As reported

RR 0.55, 95% CI 0.42–0.72

+5 more in the walkthrough ↓

Nine numbers in the abstract

the abstract, start to end

(13 studies, 36,033 participants; RR 0.72, 95% CI 0.66 to 0.79), all-cause mortality (10 studies, 28,276 participants; RR 0.79, 95% CI 0.69 to 0.91), cardiovascular death (7 studies, 19,059 participants; RR 0.77, 95% CI 0.69 to 0.87) and MI (8 studies, 9018 participants; RR 0.55, 95% CI 0.42 to 0.72).

stroke (5 studies, 8658 participants; RR 0.62, 95% CI 0.35 to 1.12).Potential harms from statin therapy were limited by lack of systematic reporting and were uncertain in analyses that had few events: elevated creatine kinase (7 studies, 4514 participants; RR 0.84, 95% CI 0.20 to 3.48), liver function abnormalities (7 studies, RR 0.76, 95% CI 0.39 to 1.50), withdrawal due to adverse events (13 studies, 4219 participants; RR 1.16, 95% CI 0.84 to 1.60), and cancer (2 studies, 5581 participants; RR 1.03, 95% CI 0.82 to 130).Statins

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
RR 0.720.66–0.79
Cardiovascular events
RR 0.790.69–0.91
Cardiovascular events
RR 0.770.69–0.87
Cardiovascular events
RR 0.550.42–0.72
Cardiovascular events
RR 0.620.35–1.12
Cardiovascular events
RR 0.840.20–3.48
Cardiovascular events
RR 0.760.39–1.50
Adverse events & safety
RR 1.160.84–1.60
Adverse events & safety
RR 1.030.82–130
StatinsCardiovascular eventsAdverse events & safety

Statins × cardiovascular eventshelps?replicated

unlikelylikely
0.86not counted

Statins × adverse events & safetyharms?mixed

unlikelylikely
0.16not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 5

74 papers cite itlatest 60 shown

2013
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2014
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 24880031